195 related articles for article (PubMed ID: 37629741)
21. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
22. GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
Chi Z; Balani J; Gopal P; Hammer S; Xu J; Peng L
J Clin Pathol; 2023 Jul; 76(7):474-479. PubMed ID: 35039449
[TBL] [Abstract][Full Text] [Related]
23. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
[TBL] [Abstract][Full Text] [Related]
24. Expression of Gata Binding Protein 3 as a Prognostic Factor in Urogenital Lesions and Its Association With Morphology.
Govardhan T; Mohapatra D; Naik S; Das P; Mohanty P; Pal A
Cureus; 2023 Nov; 15(11):e49635. PubMed ID: 38161907
[TBL] [Abstract][Full Text] [Related]
25. Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
Kaczmarek K; Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Schallenberg S; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Zecha H
Int Urol Nephrol; 2024 Feb; 56(2):499-508. PubMed ID: 37777995
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
27. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
28. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
29. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
31. Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary.
Koyanagi Y; Kubo C; Nagata S; Ryu A; Hatano K; Kano R; Tanada S; Ashimura JI; Idota A; Kamiura S; Yamasaki T; Nakatsuka SI
Diagn Pathol; 2019 Feb; 14(1):9. PubMed ID: 30711015
[TBL] [Abstract][Full Text] [Related]
32. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
33. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract][Full Text] [Related]
34. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
Esheba GE; Longacre TA; Atkins KA; Higgins JP
Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
[TBL] [Abstract][Full Text] [Related]
35. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
37. Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues.
Lu J; Zhao M; Wu C; Chu C; Zhang CZ; Cao Y
Diagn Pathol; 2022 Jan; 17(1):10. PubMed ID: 35027056
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra.
Chaux A; Han JS; Lee S; Gonzalez-Roibon N; Sharma R; Burnett AL; Cubilla AL; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2760-7. PubMed ID: 24134931
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
[TBL] [Abstract][Full Text] [Related]
40. Urothelial carcinoma of the bladder with abundant myxoid stroma: A case report and literature review.
Tao TT; Chen J; Hu Q; Huang XJ; Fu J; Lv BD; Duan Y
Medicine (Baltimore); 2020 Jul; 99(28):e21204. PubMed ID: 32664169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
